Rhea-AI Summary
Sigilon Therapeutics has announced the pricing of its upsized initial public offering (IPO) of 7,000,000 shares at $18.00 per share, aiming to raise approximately $126.0 million. The offering includes a 30-day option for underwriters to purchase an additional 1,050,000 shares. Trading is expected to commence on December 4, 2020, under the ticker symbol SGTX. The IPO is set to close on December 8, 2020, pending customary conditions. Morgan Stanley, Jefferies, Barclays, and Canaccord Genuity are the joint book-running managers for this offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags